BioNTech SE American Depositary Share - BNTX STOCK NEWS

BioNTech and Medigene have initiated a three-year collaboration to develop T cell receptor (TCR) immunotherapies for cancer. BioNTech will acquire a preclinical TCR program targeting PRAME, alongside licenses for Medigene’s PD1-41BB switch receptor and precision pairing technologies. The agreement includes an upfront payment of EUR 26 million to Medigene, with additional milestone payments and royalties based on sales. BioNTech will retain exclusive worldwide development and commercialization rights to resulting therapies, significantly enhancing its cell therapy portfolio.

BioNTech is advancing its efforts to enhance vaccine supply in Africa by developing turnkey mRNA manufacturing facilities. Key leaders from various African nations and international organizations gathered in Marburg to discuss the establishment of an end-to-end manufacturing network. The first facility is planned to start construction in mid-2022 in Senegal. Each BioNTainer can produce up to 50 million doses annually, addressing critical public health needs in the region.

BioNTech SE (Nasdaq: BNTX) announced a high-level meeting in Marburg aimed at promoting sustainable vaccine manufacturing within the African Union. This initiative, led by the kENUP foundation, includes distinguished participants such as the President of Senegal and the Director General of the WHO. Public statements will occur on February 16, 2022, followed by a digital press conference detailing BioNTech's vaccine manufacturing efforts in Africa. This meeting underscores the company's commitment to expanding its vaccine production capabilities.

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced plans to extend a rolling submission to the FDA to amend the Emergency Use Authorization for their COVID-19 vaccine, targeting children aged 6 months to 4 years. Ongoing trials are evaluating a three-dose regimen, with data expected in early April, aimed to enhance protection amidst the Omicron surge. The study involves around 8,300 children and is supported by an independent Data Monitoring Committee, underscoring the vaccine's tolerability and potential efficacy.

On February 1, 2022, Pfizer and BioNTech announced submitting data to the FDA for amending the Emergency Use Authorization (EUA) of their COVID-19 vaccine to include children aged 6 months to 4 years. The initial submission seeks authorization for two 3 µg doses, with plans for a third dose in the future. Over 10.6 million children in the U.S. have contracted COVID-19, with a notable increase in hospitalizations among children under 4. If approved, this vaccine would be the first for this age group, addressing a critical public health need.

Pfizer and BioNTech have initiated a rolling submission to amend the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include children aged 6 months to 4 years, at the request of the FDA. This application seeks authorization for two 3 µg doses as part of a planned three-dose series. With over 10.6 million pediatric COVID-19 cases in the U.S., this vaccine could be the first available for children under 5. The companies aim to submit additional data for a third dose in the coming months, enhancing protection against current and future variants.

Pfizer and BioNTech have initiated a clinical trial for an Omicron-based COVID-19 vaccine candidate aimed at healthy adults aged 18 to 55. The study will enroll up to 1,420 participants across three cohorts, evaluating different regimens of the current vaccine versus the Omicron candidate. Senior officials stress the importance of preparing for potential waning effectiveness of current vaccines. The companies continue to expect production of four billion doses in 2022, regardless of the adaptation requirements.

Pfizer and BioNTech have commenced a clinical trial for an Omicron-based COVID-19 vaccine, evaluating safety and immunogenicity in 1,420 healthy adults aged 18-55. This study will assess various dosing regimens of the existing vaccine alongside the Omicron variant candidate. With the ongoing risk of waning vaccine effectiveness against emerging variants, the companies aim to provide longer-lasting protection. The trial is part of an extensive strategy to address evolving COVID-19 challenges while maintaining production capabilities of the current vaccine.

BioNTech and InstaDeep have developed an Early Warning System (EWS) for detecting high-risk SARS-CoV-2 variants using AI. This scalable system combines structural modeling of the viral Spike protein with predictive analytics, identifying over 90% of WHO-designated variants two months in advance. The EWS can evaluate new variants in minutes and has detected variants like Omicron on the same day their sequences were uploaded. The study, available on BioRxiv, aims to enhance preparedness against future COVID-19 variants.